$4.67
3.64%
Downside
Day's Volatility :5.96%
Upside
2.4%
58.03%
Downside
52 Weeks Volatility :64.23%
Upside
14.78%
Period | Design Therapeautics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 21.3% | 5.1% | 0.0% |
6 Months | 63.86% | 4.9% | 0.0% |
1 Year | 77.57% | 16.6% | 0.0% |
3 Years | -73.47% | 13.2% | -22.3% |
Market Capitalization | 264.4M |
Book Value | $4.61 |
Earnings Per Share (EPS) | -0.9 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -13.63% |
Return On Equity TTM | -18.11% |
Revenue TTM | 33.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -48.6M |
EBITDA | -62.8M |
Diluted Eps TTM | -0.9 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.91 |
EPS Estimate Next Year | -1.17 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 49.89%
Sell
Neutral
Buy
Design Therapeautics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Design Therapeautics, Inc. | 14.46% | 63.86% | 77.57% | -73.47% | -88.74% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Design Therapeautics, Inc. | NA | NA | NA | -0.91 | -0.18 | -0.14 | NA | 4.61 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Design Therapeautics, Inc. | Hold | $264.4M | -88.74% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Design Therapeautics, Inc.
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 142.7%
SR ONE CAPITAL MANAGEMENT, LP
Logos Global Management LP
BlackRock Inc
Baker Bros Advisors LP
TANG CAPITAL MANAGEMENT LLC
Vanguard Group Inc
Organization | Design Therapeautics, Inc. |
Employees | 57 |
CEO | Mr. Pratik Shah Ph.D. |
Industry | Healthcare |